Targeting HIV Therapy with Intelligence

With an arsenal of 17 approved drugs and intricate rules for deploying each one, a physician's battle to shut down HIV replication is like chess against an opponent too strong to be driven from the board, so keeping the game going is the only alternative to losing. Today's best strategy for suppressing HIV calls for using three or four inhibitors in combination. As with a chessboard siege defense, conserving pieces while sealing off each new attack, doctors try to pick drug combinations that pre

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

With an arsenal of 17 approved drugs and intricate rules for deploying each one, a physician's battle to shut down HIV replication is like chess against an opponent too strong to be driven from the board, so keeping the game going is the only alternative to losing. Today's best strategy for suppressing HIV calls for using three or four inhibitors in combination. As with a chessboard siege defense, conserving pieces while sealing off each new attack, doctors try to pick drug combinations that preserve as many options as possible should HIV mutate into drug resistance.

To help doctors find the most promising combinations in any situation, software called the HIV Therapy Edge combines bioinformatics with artificial intelligence, a computer science discipline grown up on chess problems. Developed by Intelligent Thera-peutic Solutions of Durham, N.C., the product is in final testing, scheduled for market release sometime this summer. HIV Therapy Edge, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tom Hollon

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo